Impact BioMedical, INC. Proceeds from Long-Term Debt Issued
Impact BioMedical, INC. (IBO) reported Proceeds from Long-Term Debt Issued of $1.12 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-03-11
- Impact BioMedical, INC. proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $317.00K.
- Impact BioMedical, INC. proceeds from issuance of long-term debt for the quarter ending 2024-09-30 was -$60.00K.
- Impact BioMedical, INC. proceeds from issuance of long-term debt for the quarter ending 2024-06-30 was $384.00K.
- Impact BioMedical, INC. proceeds from issuance of long-term debt for the quarter ending 2024-03-31 was $483.00K, a 52.51% decline year-over-year.
- Impact BioMedical, INC. proceeds from issuance of long-term debt for fiscal 2024 was $1.12M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 3 month as first filed | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $257.00K derived: sum of 2 quarters · filed 2026-03-11 | $641.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.12M 10-K · filed 2026-03-11 | |
| 2024-09-30 | -$60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $324.00K derived: sum of 2 quarters · filed 2025-11-07 | $807.00K 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $867.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $483.00K 10-Q · filed 2025-05-14 | $713.00K 10-Q · filed 2024-05-10 | |||
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |